arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Relmada Therapeutics, Inc.

RLMD Health Care Biotechnology: Pharmaceutical Preparations
$3.27
▲ +1.9% Today
as of Oct 23, 16:51 ET
Last 30 days -26.35% Sep 14 → Oct 23
$2.99 $3.38 $3.77 $4.16 $4.55 Sep 14 Sep 22 Sep 30 Oct 07 Oct 15 Oct 23
Open
$3.26
High
$3.33
Low
$3.18
Volume
$1M
Avg Vol
$1M
Mkt Cap
$390M
P/E (TTM)
—
Beta
—
52w High
$8.00
52w Low
$2.07
Div Yield
—
Shares Out
$107M

Recent Press Releases & News last 60 days · 4 items

Sep 11 · 18:30 MT Newswires
Relmada Therapeutics Shares Rise After CEO, CFO Buy 200,000 Shares Each
Sep 1 · 12:00 PR GlobeNewswire
Relmada Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
Aug 31 · 13:35 Zacks
After Plunging 18.5% in 4 Weeks, Here's Why the Trend Might Reverse for Relmada Therapeutics (RLMD)
▸ Show all 4 press releases & news Free account →

RLMD earnings at a glance

The options market is pricing a move of about ±50.5% after the report, a range of roughly $1.62 to $4.92 from today's $3.27. Over its last 2 reports the stock rose the next day 1 time and fell 1, moving ±3.2% on average; after the most recent report on May 12, 2026 it moved +1.2%. That means options currently expect more movement than RLMD has typically delivered. RLMD beat the consensus EPS estimate in 0 of its last 3 reported quarters. Implied volatility is currently 427%. The share price of $3.27 sits in the middle of its 52-week range.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$2.07
$8.00
20% of range
Avg surprise (last 3)
-230.7%
Avg reaction (last 2)
-2.0%
50% positive
Latest IV / EM
427%
EM ±50.5% · $3 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.87$-0.66$-0.46$-0.25$-0.04 Actual $-0.87Actual $-0.84Actual $-0.73Actual $-0.72Actual $-0.59Actual $-0.72Actual $-0.58Actual $-0.30Est $-0.25Actual $-0.30Est $-0.04Actual $-0.22Est $-0.18Actual $-0.11 MarJunSepMarJunSepMar/2025Jun/2025Sep/2025Mar/2026Jun
Revenue vs Net Income Revenue Net income
$-22M$-19M$-16M$-13M$-10M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.11 — — — — financials
Tue May 12, 2026Mar/2026 $-0.22 $-0.18 -22.2% +62.1% +1.2% earnings
Thu Nov 13, 2025Sep/2025 $-0.30 $-0.04 -650.0% — — earnings
Thu Aug 7, 2025Jun/2025 $-0.30 $-0.25 -20.0% — — earnings
Mon May 12, 2025Mar/2025 $-0.58 — — — -5.2% earnings
Mon Sep 30, 2024Sep 2024 $-0.72 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.59 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.72 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.73 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.84 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.87 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue————————
Cost of revenue————————
Gross profit————————
Operating income$-15M$-19M—$-10M$-10M$-18M—$-23M
Net income$-13M$-19M—$-10M$-10M$-18M—$-22M
EPS (diluted)$-0.11$-0.22—$-0.30$-0.30$-0.58—$-0.72

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$11M$10M$3M$1M$1M$1M$4M$1M
Inventory————————
Total current assets$219M$235M$94M$15M$21M$28M$46M$56M
Total assets$219M$235M$94M$15M$21M$28M$46M$56M
Long-term debt————————
Total liabilities$13M$17M$7M$5M$5M$5M$10M$8M
Total equity$207M$219M$87M$9M$16M$22M$36M$48M

Implied volatility — last 90 days

61%260%458%656%855% Jun 08 — IV 255% · EM ±33.6%Jun 09 — IV 363% · EM ±45.5%Jun 10 — IV 304% · EM ±35.9%Jun 11 — IV 167% · EM ±18.4%Jun 12 — IV 136% · EM ±13.9%Jun 15 — IV 431% · EM ±31.2%Jun 16 — IV 556% · EM ±32.8%Jun 17 — IV 617% · EM ±25.8%Jun 19 — IV 103% · EM ±22.7%Jun 22 — IV 97% · EM ±20.3%Jun 23 — IV 96% · EM ±19.6%Jun 24 — IV 90% · EM ±18.0%Jun 25 — IV 105% · EM ±20.5%Jun 26 — IV 115% · EM ±22.0%Jun 29 — IV 97% · EM ±17.2%Jun 30 — IV 92% · EM ±15.9%Jul 01 — IV 110% · EM ±18.4%Jul 02 — IV 231% · EM ±37.4%Jul 03 — IV 239% · EM ±37.4%Jul 06 — IV 268% · EM ±37.1%Jul 07 — IV 334% · EM ±44.1%Jul 08 — IV 280% · EM ±35.1%Jul 09 — IV 234% · EM ±27.6%Jul 10 — IV 332% · EM ±36.7%Jul 13 — IV 427% · EM ±35.7%Jul 14 — IV 590% · EM ±42.7%Jul 15 — IV 654% · EM ±38.6%Jul 16 — IV 460% · EM ±19.2%Jul 20 — IV 91% · EM ±21.4%Jul 21 — IV 73% · EM ±16.9%Jul 22 — IV 79% · EM ±18.0%Jul 23 — IV 62% · EM ±13.9%Jul 24 — IV 76% · EM ±16.9%Jul 27 — IV 83% · EM ±17.3%Jul 28 — IV 89% · EM ±18.2%Jul 29 — IV 87% · EM ±17.5%Jul 30 — IV 86% · EM ±16.8%Jul 31 — IV 89% · EM ±16.9%Aug 03 — IV 83% · EM ±14.6%Aug 04 — IV 104% · EM ±17.8%Aug 05 — IV 154% · EM ±25.7%Aug 06 — IV 149% · EM ±24.1%Aug 07 — IV 98% · EM ±15.2%Aug 10 — IV 139% · EM ±19.3%Aug 11 — IV 203% · EM ±26.8%Aug 12 — IV 101% · EM ±12.7%Aug 13 — IV 98% · EM ±11.6%Aug 14 — IV 99% · EM ±10.9%Aug 17 — IV 163% · EM ±13.6%Aug 19 — IV 193% · EM ±11.4%Aug 20 — IV 387% · EM ±16.2%Aug 24 — IV 86% · EM ±18.0%Aug 25 — IV 101% · EM ±20.7%Aug 26 — IV 126% · EM ±25.3%Aug 27 — IV 136% · EM ±26.5%Aug 28 — IV 146% · EM ±27.8%Aug 31 — IV 207% · EM ±36.7%Sep 01 — IV 176% · EM ±30.3%Sep 02 — IV 122% · EM ±20.4%Sep 03 — IV 163% · EM ±26.3%Sep 04 — IV 217% · EM ±33.9%Sep 07 — IV 244% · EM ±33.9%Sep 08 — IV 160% · EM ±21.2%Sep 09 — IV 342% · EM ±42.8%Sep 10 — IV 406% · EM ±47.9%Sep 11 — IV 209% · EM ±23.1%Sep 14 — IV 351% · EM ±29.3%Sep 15 — IV 342% · EM ±24.8%Sep 16 — IV 502% · EM ±29.6%Sep 17 — IV 855% · EM ±35.7%Sep 21 — IV 115% · EM ±24.0%Sep 22 — IV 196% · EM ±40.1%Sep 23 — IV 363% · EM ±72.8%Sep 24 — IV 342% · EM ±66.9%Sep 25 — IV 334% · EM ±64.0%Sep 28 — IV 365% · EM ±64.6%Sep 29 — IV 420% · EM ±72.4%Sep 30 — IV 402% · EM ±67.1%Oct 01 — IV 448% · EM ±72.4%Oct 02 — IV 453% · EM ±70.8%Oct 06 — IV 450% · EM ±59.5%Oct 07 — IV 405% · EM ±50.8%Oct 08 — IV 427% · EM ±50.5%

Sector peers

TTRX
Turn Therapeutics Inc.
$396M $10.28+1.3%
EBS
Emergent BioSolutions Inc.
$363M $6.23+0.5%
BNTC
Benitec Biopharma Inc.
$334M $8.65+1.8%
DMAC
DiaMedica Therapeutics Inc.
$450M $8.72+0.3%
EVMN
Evommune, Inc.
$472M $5.10-1.4%
PRLD
Prelude Therapeutics Incorporated
$302M $3.63-0.6%

RLMD earnings FAQ

What is RLMD's expected move for earnings?

Options currently price a move of about ±50.5%, or $1.65 per share either way from $3.27.

How does RLMD stock usually react to earnings?

Across the last 2 reports the average next-day move was ±3.2%, up 1 times and down 1 times.

What is RLMD's implied volatility?

RLMD's at-the-money implied volatility is about 427% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in